Marinus Pharmaceuticals Statistics
Share Statistics
Marinus Pharmaceuticals has 55.19M shares outstanding. The number of shares has increased by 0.94% in one year.
| Shares Outstanding | 55.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 41.87M |
| Failed to Deliver (FTD) Shares | 40.43K |
| FTD / Avg. Volume | 1.55% |
Short Selling Information
The latest short interest is 5.66M, so 10.26% of the outstanding shares have been sold short.
| Short Interest | 5.66M |
| Short % of Shares Out | 10.26% |
| Short % of Float | 13.54% |
| Short Ratio (days to cover) | 1.09 |
Valuation Ratios
The PE ratio is -4.13 and the forward PE ratio is -0.49.
| PE Ratio | -4.13 |
| Forward PE | -0.49 |
| PS Ratio | 18.85 |
| Forward PS | 0.2 |
| PB Ratio | 34.85 |
| P/FCF Ratio | -4.95 |
| PEG Ratio | n/a |
Enterprise Valuation
Marinus Pharmaceuticals Inc. has an Enterprise Value (EV) of 574.01M.
| EV / Earnings | -4.06 |
| EV / Sales | 18.52 |
| EV / EBITDA | -4.57 |
| EV / EBIT | -4.37 |
| EV / FCF | -4.86 |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 6.5.
| Current Ratio | 4.07 |
| Quick Ratio | 4.01 |
| Debt / Equity | 6.5 |
| Total Debt / Capitalization | 86.66 |
| Cash Flow / Debt | -1.08 |
| Interest Coverage | -7.78 |
Financial Efficiency
Return on equity (ROE) is -8.43% and return on capital (ROIC) is -102.32%.
| Return on Equity (ROE) | -8.43% |
| Return on Assets (ROA) | -0.83% |
| Return on Capital (ROIC) | -102.32% |
| Revenue Per Employee | 187.81K |
| Profits Per Employee | -857.00K |
| Employee Count | 165 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.8 |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -96.97% in the last 52 weeks. The beta is 1.26, so Marinus Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -96.97% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 27.53 |
| Average Volume (20 Days) | 2.61M |
Income Statement
In the last 12 months, Marinus Pharmaceuticals had revenue of $30.99M and earned -$141.41M in profits. Earnings per share was $-2.63.
| Revenue | 30.99M |
| Gross Profit | 29.05M |
| Operating Income | -131.49M |
| Net Income | -141.41M |
| EBITDA | -125.50M |
| EBIT | -131.49M |
| Earnings Per Share (EPS) | -2.63 |
Balance Sheet
The company has $120.57M in cash and $110.36M in debt, giving a net cash position of $10.21M.
| Cash & Cash Equivalents | 120.57M |
| Total Debt | 110.36M |
| Net Cash | 10.21M |
| Retained Earnings | -571.93M |
| Total Assets | 63.62M |
| Working Capital | 22.90M |
Cash Flow
In the last 12 months, operating cash flow was -$118.00M and capital expenditures -$119.00K, giving a free cash flow of -$118.12M.
| Operating Cash Flow | -118.00M |
| Capital Expenditures | -119.00K |
| Free Cash Flow | -118.12M |
| FCF Per Share | -2.2 |
Margins
Gross margin is 93.76%, with operating and profit margins of -424.3% and -456.31%.
| Gross Margin | 93.76% |
| Operating Margin | -424.3% |
| Pretax Margin | -461.27% |
| Profit Margin | -456.31% |
| EBITDA Margin | -404.97% |
| EBIT Margin | -424.3% |
| FCF Margin | -381.17% |
Dividends & Yields
MRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1011.54% |
| FCF Yield | -826.41% |
Analyst Forecast
The average price target for MRNS is $2.5, which is 861.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.5 |
| Price Target Difference | 861.5% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
Stock Splits
The last stock split was on Sep 23, 2020. It was a backward split with a ratio of 1:4.
| Last Split Date | Sep 23, 2020 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -20.16 |
| Piotroski F-Score | 3 |